低分子肝素结合神经节苷酯治疗急性进展型脑梗死的临床分析

Clinical analysis of low-molecular-weight heparin combined with ganglioside in treatment of acute progressive cerebral infarction

摘要:

目的 观察应用低分子肝素与神经节苷脂联合治疗急性进展型脑梗死的临床疗效.方法 选取2010年3月至2012年6月在我院确诊为患有急性进展型脑梗死且进行治疗的患者84例,随机将患者分为两组,治疗组的42例患者采用低分子肝素与神经节苷脂联合进行治疗,对照组的42例患者则采用传统药物,即灯盏花素、阿司匹林与立普妥进行治疗.然后对两组患者的治疗效果进行比较,治疗效果以神经功能缺损程度评分(NFDS)来判断.结果 两组患者在治疗前NDFS评分差异没有统计学意义.两组患者在治疗2周以及4周后NDFS评分均改善,差异有统计学意义(P<0.05);且治疗组较对照组改善更为明显(P<0.05).结论 应用低分子肝素与神经节苷脂联合治疗急性进展型脑梗死有较好的临床疗效,可明显改善临床症状,降低病死率,且安全可靠,对患者的生活质量有明显的提高,值得在临床上进行推广.

Abstract:

Objective To investigate the clinical efficacy of low-molecular-weight heparin (LMWH) combined with ganglioside (GLS) in the treatment of acute progressive cerebral infarction (APCI).Methods Eighty-four patients diagnosed with APCI and treated in our hospital from March 2010 to June 2012 were randomly divided into two groups. In the treatment group, 42 patients were administered LMWH combined with GLS, and in the control group, 42 patients were administered traditional medicines, including breviscapine, aspirin, and Lipitor. The therapeutic effects of drugs were compared between the two groups and evaluated using the neurological functional deficit score (NFDS).Results The NFDS score had no significant difference between groups before treatment and significantly increased in both groups after 2 and 4 weeks of treatment (P<0.05). The increase in NFDS score was more significant in the treatment group than in the control group (P<0.05).Conclusions Application of LMWH combined with GLS has good clinical efficacy in the treatment of APCI. This medication can significantly alleviate the clinical symptoms and reduce the mortality rate of APCI. It is safe, reliable, and effective to significantly improve the quality of life of patients, and thus is worthy of wide clinical application.